Investigational Drug Details
| Drug ID: | D364 |
| Drug Name: | Sevoflurane |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB01236 |
| DrugBank Description: | Sevoflurane, also called fluoromethyl, is an ether inhalation anaesthetic agent used for the induction and maintenance of general anesthesia. It is a volatile, non-flammable, non-irritant, and easy-to-administer compound with a low solubility profile and blood-to-gas partition coefficient. |
| PubChem ID: | 5206 |
| CasNo: | 28523-86-6 |
| Repositioning for NAFLD: | Yes |
| SMILES: | FCOC(C(F)(F)F)C(F)(F)F |
| Structure: |
|
| InChiKey: | DFEYYRMXOJXZRJ-UHFFFAOYSA-N |
| Molecular Weight: | 200.0548 |
| DrugBank Targets: | GABA-A receptor (anion channel); Glycine receptor subunit alpha-1; Glutamate receptor 1; NA; NADH-ubiquinone oxidoreductase chain 1; NA |
| DrugBank MoA: | Sevoflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Sevoflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase and also binds to the GABA receptor, the large conductance Ca<sup>2+</sup> activated potassium channel, the glutamate receptor, and the glycine receptor. |
| DrugBank Pharmacology: | Sevoflurane induces muscle relaxation and reduces pains sensitivity by altering tissue excitability with a fast onset of action. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential. |
| DrugBank Indication: | Used for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L2763 | NCT05324462 | COMPLETED | NO | 2022-03-22 | 2022-11-09 | Details | |
| L3439 | NCT03620773 | PHASE1|PHASE2 | ACTIVE_NOT_RECRUITING | NO | 2018-10-01 | 2024-04-05 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|